Efficacy Study of Canakinumab to Treat Urticaria

Sponsor
University of Zurich
Study ID
NCT01635127
Phase
PHASE2
Status
Unknown

Conditions

  • Chronic Idiopathic Urticaria

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Canakinumab — DRUG
    150mg s.c.
  • Placebo — DRUG
    Constituent of canakinumab

Study Details

Evaluation whether canakinumab leads to improvement of urticaria

Key Dates

Start date
Jun 30, 2012
Status verified
Sep 2016
Primary completion
Dec 31, 2016
Completion
May 31, 2017

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Canakinumab
    Monoclonal antibody inhibiting interleukin 1 beta
  • Placebo Comparator: Placebo
    Constituent, inactive

Primary Outcome Measure

Complete clinical remission [ Time Frame: 4 weeks ]

Central Contacts